Skip to main content
NANOVIRICIDES, INC. logo

NANOVIRICIDES, INC. — Investor Relations & Filings

Ticker · NNVC ISIN · US6300873022 LEI · 5493003CK9Y2H0OORR73 US Professional, scientific and technical activities
Open in API
Filings indexed 536 across all filing types
Latest filing 2012-10-15 Annual Report
Country US United States of America
Listing US NNVC

About NANOVIRICIDES, INC.

https://www.nanoviricides.com/

NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing a novel class of nanomedicine-based antiviral therapeutics. The company's proprietary platform technology creates "nanoviricides," which are designed to be broad-spectrum drugs that viruses cannot easily evade through mutation. The technology is biomimetic, mimicking the host cell receptors that viruses use for entry. A nanoviricide is engineered to attract and bind to a virus particle, subsequently trapping and dismantling it to neutralize the threat. The company's development pipeline targets a wide range of viral infections, including respiratory viruses such as RSV, influenza, and coronaviruses, as well as herpesviruses (shingles, cold sores), HIV, and hemorrhagic fever viruses.

Recent filings

Filing Released Lang Actions
FORM 10-K
Annual Report FY 2012
2012-10-15 English
NOTICE UNDER RULE 12B25
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a notification of late filing for a Form 10-K annual report. It explicitly states that the company could not file its Annual Report on Form 10-K for the period ended June 30, 2012, within the prescribed time and is notifying the SEC of this delay. The document does not contain the actual 10-K report or financial data but is a regulatory notification about the late filing. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document and not the report itself.
2012-09-28 English
Regulatory Filings 2012
Regulatory Filings
2012-07-10 English
AMENDMENT TO FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a Form 8-K current report filed with the SEC. It details the entry into a material definitive agreement related to a securities purchase agreement for convertible preferred stock. The content focuses on financing activities, including the terms of the offering, conversion mechanics, and related agreements. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a call transcript, management report, or governance information. It is clearly an update on capital raising and financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (9419 characters) supports it being a substantive filing rather than a brief announcement or certification, increasing confidence in this classification.
2012-06-30 English
8-K CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 26, 2012. It details the entry into a material definitive agreement related to the offering and sale of Series C Convertible Preferred Stock by NanoViricides, Inc. The content focuses on the terms of the securities purchase agreement, the offering details, conversion mechanics, and related agreements. There are no financial statements or comprehensive financial performance data included. The document is primarily an announcement of a financing transaction and related agreements, which fits the category of Capital/Financing Update. The document length (9411 characters) is sufficient to contain substantive details about the financing but does not constitute a full financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2012-06-29 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by NanoViricides, Inc. It details the terms of the offering of Series C Convertible Preferred Stock and Common Stock, including pricing, conversion terms, use of proceeds, and placement agent information. The document is a formal registration and offering document used to raise capital and does not contain financial statements or earnings data. It is not an annual report, earnings release, or management discussion. It is clearly a capital raising disclosure document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed offering terms support this classification with high confidence.
2012-06-28 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.